Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Virbac S.A. is a global player in the animal health industry, specializing in the development and marketing of veterinary pharmaceuticals and vaccines. The company has a strong presence in Europe, Latin America, and Asia, with a diverse product portfolio that includes parasiticides, antibiotics, and vaccines, which are critical for livestock and companion animals.
Virbac generates revenue primarily through the sale of veterinary pharmaceuticals and vaccines, leveraging its R&D capabilities to innovate and maintain a competitive edge. The company benefits from strong pricing power due to the specialized nature of its products and a loyal customer base among veterinarians and pet owners.
Regulatory approvals for new veterinary drugs and vaccines
Market expansion in emerging economies, particularly in Asia and Latin America
Changes in livestock health trends and consumer preferences for pet care
Fluctuations in raw material costs impacting margins
Regulatory changes affecting product approvals and market access
Technological advancements in veterinary medicine that could disrupt current product lines
Increasing competition from generic animal health products
Market entry of larger pharmaceutical companies into the veterinary space
Potential liquidity risks if cash flow generation does not meet expectations
Currency fluctuations affecting international revenues
moderate - The demand for animal health products can be somewhat insulated from economic cycles, but overall consumer spending and livestock production trends can influence revenue.
Virbac's operations are less sensitive to interest rates as it maintains a low debt-to-equity ratio (0.26), but higher rates could impact consumer spending on pet care products and financing costs for expansion.
minimal - The company has a strong balance sheet with low debt levels, reducing its reliance on credit markets.
growth - Investors are likely attracted to Virbac due to its consistent revenue growth and expansion into new markets.
moderate - The stock has shown some volatility, but its fundamentals provide a degree of stability.